Papers on HbA1c <7%

107 papers9 new in 30 days

Friday, June 14

LancetJun 14

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Randomized trial in 9,901 peopleDulaglutide

Paper

Friday, June 7

BMC Endocrine DisordersJun 7

Factors associated with glycemic control in community-dwelling elderly individuals with type 2 diabetes mellitus in Zhejiang, China: a cross-sectional study

Study in peopleBiomarkers

Paper

Thursday, December 20

Diabetes, Obesity & MetabolismDec 20

Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom

Computational studySGLT2 inhibitors

Paper

Thursday, October 4

LancetOct 4

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Randomized trial in 316 peopleGLP-1 receptor agonists

Paper

Thursday, September 6

Diabetes CareSep 6

Long-term Glycemic Control and Dementia Risk in Type 1 Diabetes

Study in peoplePopulations

Paper

Wednesday, June 20

Journal of Family Medicine and Primary CareJun 20

Evaluation of treatment satisfaction, efficacy and safety of dipeptidyl peptidase-4 inhibitors in geriatric patients with type 2 diabetes mellitus: A cross-sectionalcomparative study

Study in peopleInterventions

Paper

Thursday, February 1

The Lancet Diabetes & EndocrinologyFeb 1

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Randomized trial in 1,201 peopleSemaglutide

Paper

Tuesday, December 12

Journal of Atherosclerosis and ThrombosisDec 12

Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes

Non-randomized trial in 50 peopleDapagliflozin

Paper

Friday, September 1

MedicineSep 1

Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus

Cohort study of 192 peopleMetformin

Paper

Thursday, June 23

Diabetes Research and Clinical PracticeJun 23

Glycemic control, cognitive function, and family support among middle-aged and older Hispanics with diabetes: The Hispanic Community Health Study/Study of Latinos

Study in peoplePopulations

Paper

Friday, May 27

Osteoporosis InternationalMay 27

The association between glucose metabolism status, diabetes severity and a history of fractures and recent falls in participants of 50 years and older-the Maastricht Study

Study in peoplePopulations

Paper

Thursday, April 14

American Journal of HypertensionApr 14

Prediabetes and Diabetes Are Associated With Arterial Stiffness in Older Adults: The ARIC Study

Study in peoplePopulations

Paper

Saturday, January 30

Current Medical Research and OpinionJan 30

Factors that influence the efficacy of acarbose and metformin as initial therapy in Chinese patients with newly diagnosed type 2 diabetes: a subanalysis of the MARCH trial

Study of 657 peopleMetformin

Paper

Thursday, January 15

Journal of DiabetesJan 15

Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus

Randomized trial in 95 peopleType 2 diabetes

Paper

Monday, December 1

The American Journal of MedicineDec 1

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

Randomized trial in 94 peopleMetformin

Paper

Wednesday, June 1

Diabetes CareJun 1

Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study

Randomized trial in 96 peopleInterventions

Paper